Lupus Nephritis Pipeline Global Market Covering Therapeutic Development for H2 2016

PUNE, India, November 1, 2016 /PRNewswire/ --

ReportsnReports.com adds "Lupus Nephritis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.  

Complete report on Lupus Nephritis Market Research with 37 market data tables and 15 figures, spread across 142 pages is available at http://www.reportsnreports.com/reports/729119-lupus-nephritis-pipeline-review-h2-2016.html .

Companies discussed in this research report include AbbVie Inc, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Aurinia Pharmaceuticals Inc, Azano Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Deltanoid Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, HanAll Biopharma Co., Ltd., Invion Limited, KPI Therapeutics, Inc., MedImmune, LLC, Omeros Corporation, Ra Pharmaceuticals, Inc., Resolve Therapeutics, LLC, Takeda Pharmaceutical Company Limited and TxCell SA. Drug Profiles mentioned in this research are abatacept, anifrolumab, belimumab, BI-655064, BMS-986147, dalazatide, DP-001, Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis, ENTX-DN, HL-161, INV-103, ixazomib citrate, mizoribine, Monoclonal Antibody for Lupus Nephritis, obinutuzumab, OMS-721, P-Dex, RA-101495, RO-5461111, RSLV-145, Stem Cell Therapy for Autoimmune Diseases, Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders, venetoclax, voclosporin and Y-175L.

Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. Symptoms include weight gain, high blood pressure, dark urine and foamy, frothy urine. Treatment includes corticosteroids, immunosuppressive drugs and health lifestyle. Lupus Nephritis pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=729119 .

The research outlays comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Another newly published market research report titled on Schistosomiasis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Kancera AB, LondonPharma Ltd, Merck KGaA and Salvensis. Schistosomiasis Pipeline market research report of 39 pages is available at http://www.reportsnreports.com/reports/729129-schistosomiasis-pipeline-review-h2-2016.html .

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
2nd floor, metropole, Next to inox theatre, Bund garden road,
Pune-411001
Maharashtra, India.
Tel: +1-888-391-5441
sales@reportsnreports.com

Connect With Us on:
Facebook:https://www.facebook.com/ReportsnReports/
LinkedIn:https://www.linkedin.com/company/reportsnreports
Twitter:https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml